摘要
The PACIFIC study ushered in a“tsunami-like”therapeutic revolution for stage III inoperable non-small cell lung cancer(NSCLC)In the past,chemoradiotherapy(CRT)has been the standard of care for inoperable stage III NSCLC.Concurrent chemoradiotherapy(cCRT),if tolerable in patients,is the optimal treatment regimen.A meta-analysis has shown that cCRT results in a 5-year survival rate 4.5%longer than that with sequential chemoradiotherapy(sCRT)1.However,within 2 years after cCRT,approximately 30%of patients experience local recurrence,and approximately 40%develop distant metastasis2.Clinicians have explored induction chemotherapy3,consolidation chemotherapy4,and combination use with targeted drugs2,and found that none improve the prognosis.
基金
The study was supported by the National Natural Science Foundation of China(Grant No.82072562 to QZ)
the High Level Hospital Construction Project(Grant No.DFJH201810 to QZ).
